<DOC>
	<DOCNO>NCT00925535</DOCNO>
	<brief_summary>Approximately 1/3 person live HIV infection co-infected tuberculosis ( TB ) . Rifabutin , use treatment TB , inducer drug metabolism thus may decrease concentration lersivirine co-administered . Lersivirine modest inducer drug metabolism , thus lersivirine may decrease concentration rifabutin well .</brief_summary>
	<brief_title>Drug Interaction Study Between Rifabutin And Lersivirine ( UK-453,061 )</brief_title>
	<detailed_description />
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease . History regular alcohol consumption exceed 7 drinks/week woman 14 drinks/week men ( 1 drink = 150 mL wine 360 mL beer 45 mL hard liquor ) . Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day . Hypersensitivity/allergic reaction component study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Pharmacokinetics HIV Tuberculosis Lersivirine UK-453</keyword>
	<keyword>061 Rifabutin</keyword>
	<keyword>HIV Infections</keyword>
</DOC>